
# In Silico Comparison of Photons versus Carbon Ions in Single Fraction Therapy of Lung Cancer



Kristjan Anderle







## Introduction



# Most Common Cancers Worldwide in 2012



#### Most Common Causes of Cancer Death Worldwide in 2012






# Stereotactic Body Radiation Treatment (SBRT)




- High precision treatment with photons
- Delivers high dose (up to 30 Gy)
  in few fractions (1-3)
- Good results for lung cancer in early stages
- Limited for:
  - Multiple tumors
  - Large tumors





# **3D Treatment Plan Example**






## **Particle Therapy**



- Advantageous dose profile for radiotherapy
- Bragg peak depends on particle energy
- No or small dose tail after the Bragg peak
- Currently, mostly static targets are treated (head & neck, pelvic)




Source:NIRS,2016



## **Motion Effects in Particle Therapy**



### Range Changes



#### Interplay







## **Motion Effects in Particle Therapy**



#### Range Changes



#### Interplay



#### **Compensations:**

- Include range-changes in target definition (range ITV)
- Optimization in all motion states (4D-optimization)

 Rescanning: instead of delivering the whole dose at once, it is delivered in N steps



## In Silico Study



- Comparison of lung cancer treatment simulations between SBRT and active scanning carbon-ions (PT)
- 23 lung cancer patients were actually treated with SBRT
- Comparison:
  - Dose to the tumor
  - Dose to critical organs
  - Dose escalation





## **Treatment planning – Cohort I**




- 19 patients, 26 tumors
- Planning objectives:
  - Single fraction of 24 Gy
  - Tumor  $D_{99\%} > 100\%$
  - Critical organs limits
- Single field uniform optimization with range ITV
- 10 dose calculations per patient:
  - Without motion, static (end-inhale and end-exhale)
  - With motion, without compensation, 4D-interplay (4x)
  - With motion, with compensation, 4D-rescanning (4x)



# **Treatment Plan Examples**








# **Treatment Plan Examples**








## **Results – Dose to Tumors**



No difference in tumor dose between SBRT and static PT (3D)






### **Results – Dose to Tumors**



- No difference in tumor dose between SBRT and static PT (3D)
- Without motion compensation the tumor dose is too low (4D interplay)






#### **Results – Dose to Tumors**




- No difference in tumor dose between SBRT and static PT (3D)
- Without motion compensation the tumor dose is too low (4D interplay)
- Rescanning mitigates tumor motion sufficiently (4D rescan)





# **Results - Dose to Critical Organs**





### **Clinical Trial RTOG 0617**




- A RTOG 0617 trial compared 60 Gy and 74 Gy dose to tumors
- In contrast to inital hypothesis, higher dose led to higher mortality
- The only significant difference between two groups was dose to the heart (V5)

(Bradley, JD et al, Lancet Oncology, 2015)



# **Average Heart V5**







## **Treatment planning – Cohort II**



- 8 patients, 24 tumors
- Different fractionation schemes
  - 3 tumors in 2 patients received 3 x 9 Gy
  - 2 tumors received 1 x 20 Gy
  - 1 tumor received 1 x 22 Gy
  - 1 tumor received 5 x 7 Gy
  - All others 1 x 24 Gy
- Intensity modulated particle therapy optimization with rescanning
  - Range ITV
  - 4D-optimization



# **Treatment planning – Cohort II**



- 8 patients, 24 tumors
- Different fractionation schemes
  - 3 tumors in 2 patients received 3 x 9 Gy
  - 2 tumors received 1 x 20 Gy
  - 1 tumor received 1 x 22 Gy
  - 1 tumor received 5 x 7 Gy
  - All others 1 x 24 Gy
- Intensity modulated particle therapy optimization with rescanning
  - Range ITV
  - 4D-optimization

Dose ecalation to 1 x 24 Gy



# Intensity Modulated Particle Therapy Optimization for Multiple Targets





Target 1 & 2 Target 1 Target 2 Each target optimized individually: **Targets** optimized simultaneously: 25 75 105 ose (%) 50 100




## **Treatment Plan Examples**









All 5 targets received planned dose with SBRT and PT (CTV  $D_{99\%} > 100 \%$ )



## **Treatment Plan Examples**





Heart

**Target** 

PT

Esophagus








Planning dose not met with PT (SBRT  $D_{99\%} = 100\%$ , PT  $D_{99\%} = 75\%$ )



## **Results – Dose to Critical Organs**









# **Average Heart V5**






## **Results – Dose Escalation**








1 tumor: 1 x 22 Gy 2 tumors: 1 x 21 Gy 2 tumors: 3 x 9 Gy

5 tumors: 1 x 24 Gy



## **Heart Dose Volume Histogram**







### **Conclusions**



- PT delivers the same dose to tumors as SBRT,
  while depositing significantly less dose to normal tissue
- PT could deliver full ablative dose in single fraction, where SBRT could not

- Patient selection for PT:
  - ✓ Multiple targets
  - ✓ Large tumors
  - x Small tumors with large motions



### **Outlook**



- First lung cancer patients treated with active scanning carbon-ions at NIRS, Chiba (Japan)
- As part of a LOEWE grant, results from this study will be used for actual lung cancer treatment at MIT – especially the multiple target case.





Exzellente Forschung für Hessens Zukunft



## **Acknowledgments**



**GSI** 

C. Graeff

M. Durante

A. Eichhorn

M. Prall

S. Hild

FC

J. Stroom

C. Greco

N. Pimentel

S. Vierra

**UK Erlangen** 

C. Bert

T. Brandt

J. Wölfelschneider





Universitätsklinikum Erlangen



